Mirabegron Stada (Mirabegron)

Mirabegron works by selectively stimulating beta‑3 adrenergic receptors in the detrusor smooth muscle of the bladder. This activation relaxes the muscle, allowing the bladder to hold a larger volume of urine and decreasing involuntary contractions that cause urgency and leakage.

The dose of Mirabegron Stada is determined by the prescribing healthcare professional based on the individual’s condition, renal function, and response to therapy. Common practice starts with a low dose that may be titrated, but exact dosing should always follow the prescriber’s instructions.

Safety data for Mirabegron Stada in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Mirabegron Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron offers a non‑anticholinergic alternative for overactive bladder. Unlike antimuscarinics, it does not commonly cause dry mouth or constipation, but it may raise blood pressure in some patients. Choice of therapy depends on individual tolerability, comorbidities and physician assessment.

Mirabegron Stada should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Mirabegron Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include significant hypertension, urinary retention that may require catheterisation, and rare severe allergic reactions such as anaphylaxis. Patients should be monitored for elevated blood pressure, difficulty emptying the bladder, and any signs of hypersensitivity.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to Mirabegron or any excipients. Caution is also advised for individuals with significant renal or hepatic impairment, and it should be avoided in those taking strong CYP2D6 inhibitors without medical supervision.